medigraphic.com

2004, Number s2

<< Back Next >>

Arch Cardiol Mex 2004; 74 (s2)

Relevance of the combined TIMI flow/perfusion index to effective assessment of reperfusion regimens with or without tirofiban in ST-elevation myocardial infarction

Martínez RMA, Rosas M, González H, Peña DMA, Martínez SC, Gaspar J, García H, Gaxiola E, Delgado L, Carrillo J, Leyva JL, Lupi E

Language: English
References: 33
Page: 394-405
PDF size: 126.62 Kb.


ABSTRACT

Beyond successful epicardial reperfusion (TIMI 3 flow), optimal myocardial reperfusion for ST-elevation myocardial infarction also requires a complete reestablishment of blood flow at the coronary microvasculature (TMP grade 3). In this Study, Tirofiban as conjunctive therapy for lytic and stenting regimens, improved not only the TIMI 3 flow rates, but also the TMPG 3 rates, which were related with a better clinical outcome without an increase in the risk of major bleeding. This study supports the hypothesis that platelets play a key role not only in the atherothrombosis process, but also in the disturbances of microcirculation and tissue perfusion. TIMI flow/perfusion index (TFP) is proposed to be used for the analysis of any new reperfusion regimen.


REFERENCES

  1. TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med 1985; 312: 932-936.

  2. Lee KL, Woodlief LH, Topol EJ, et al: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from international trial of 41,021 patients. Circulation 1995; 91: 1659-1668.

  3. Armstrong PW, Granger C, Van de Werf F: Bolus Fibrinolysis: Risk, benefit, and opportunities. Circulation 2001; 103: 1171-1173.

  4. Rezkalla SH, Kloner RA: No-Reflow Phenomenon. Circulation 2002; 105: 656-662.

  5. Sutton AGC, Campell PG, Grech ED, et al: Failure of thrombolysis: experience with a policy of early angiography and rescue angioplasty for electrocardiographic evidence of failed thrombolysis. Heart 2000; 84: 197-204.

  6. de Belder MA: Acute Myocardial Infarction: Failed Thrombolysis. Heart 2001; 85: 104-112.

  7. Kucia MA, Jame CZ: Failed reperfusion after thrombolytic therapy recognition and management. Heart & Lung 2002; 31: 113-121.

  8. Davies CH, Ormerod OJM: Failed coronary thrombolysis. Lancet 1998; 351: 1191-1196.

  9. Cannon CP: Overcoming thrombolytic resistance. Rationale and initial experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1395-1402.

  10. Gibson MC: Primary angioplasty compared with thrombolysis: New issues in the era of glycoprotein IIb/IIIa inhibition and coronary stenting. Ann Intern Med 1999; 130: 841-847.

  11. Watson DSR, Chin BSP, Lip GYH: Antithrombotic therapy in acute coronary syndromes. BMJ 2002; 325: 1358-1355.

  12. Ohman EM, Kleiman NS, Gacioch G, et al: Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846-854.

  13. Antman EM, Giugliano RP, Gibson MC, et al: Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-2732.

  14. de Lemos JA, Antman EM, Gibson MC, et al: Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from TIMI 14 trial. Circulation 2000; 101: 239-243.

  15. Brener SJ, Zeymer U, Adgey JAA, et al: Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39: 377-386.

  16. Veselka J, Tesar D, Mates M: Coronary stenting without predilatation: a clinical routine with Jomed Delivery System Catheter Cardiovasc Interv. 1999; 46(1):121-2.

  17. Gulba DC, Tanswell P, Dechend R, et al: Six-Minute Alteplase Protocol: A New Accelerated Recombinant Tissue-type Plasminogen Activator Regimen for Thrombolysis in Acute Myocardial Infarction. J Am Coll Cardiol 1997; 30: 1611-7.

  18. The GUSTO angiographic investigators: The effects of tissue plasminogen activatior, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.

  19. Gibson CM, Cannon CP, Murphy SA, et al: For the TIMI study group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130.

  20. Gibson MC, Cannon CP, Murphy SA, et al: Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.

  21. Neuhaus KL, Jeep-Teebe S, Niederer W, et al: Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatior. J Am Coll Cardiol 1989; 14: 1566-1569.

  22. Bailar JC III, Mosteller F, eds. Medical uses of statistics. 2nd ed. Waltham, Mass.: NEJM Books, 1992: 261-9, 281-291.

  23. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.

  24. Fergusson D, Aaron SD, Guyatt G, et al: Post-randomization exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002; 325: 652-654.

  25. Schomig A, Kastrati A, Dirschinger J, et al: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000; 343: 385-391.

  26. Stone GW, Grines CL, Cox DA, et al: Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction (CADILLAC) investigators. N Engl J Med 2002; 346: 957-966.

  27. Topol EJ: Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97: 211-218.

  28. Van de Werf F, Baim DS: Reperfusion for ST-segment elevation myocardial infarction: An overview of current treatment options. Circulation 2002; 105: 2813-2816.

  29. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

  30. Ruggeri ZM: Platelets in atherothrombosis. Nature Medicine 2002; 8: 1227-1234.

  31. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Crit Care Med 2002; 30(Suppl.): S332-S340.

  32. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189-198.

  33. Ellis SG, Sliva ER, Heyndrickx G, et al: For the RESCUE investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994; 90: 2280-2284.




2020     |     www.medigraphic.com